Monoclonal antibody or antigen-binding fragment that binds to the human trbv5-1 segment, use

CL202601084A1Pending Publication Date: 2026-07-10JOINT CO BIOCAD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CL202601084
Authority / Receiving Office
CL · CL
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-04
Filing Date
2026-04-06
Publication Date
2026-07-10
Patent Text Reader

Abstract

The present invention relates to the fields of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to the TRBV5-1 segment of the beta chain variable domain of the human T-cell receptor. The invention also relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing them, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, and methods for the treatment or prophylaxis of diseases or disorders mediated by the TRBV5-1 segment of the beta chain variable domain of the human T-cell receptor.The uses of antibodies or pharmaceutical compositions thereof for the treatment or prophylaxis of diseases or disorders mediated by the TRBV5-1 segment of the variable domain of the beta chain of the human T cell receptor, and the uses of antibodies according to the invention and other therapeutically active compounds for the treatment or prophylaxis of diseases or disorders mediated by the TRBV5-1 segment of the variable domain of the beta chain of the human T cell receptor.
Need to check novelty before this filing date? Find Prior Art